Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma

NCT00329719 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00329719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00329719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Completed
Start date
March 24, 2006
Completion date
February 2, 2013
Enrollment
115 (actual)
Sites
190

Conditions

As the registry lists them; a condition with its own page is linked.

adult glioblastoma, adult gliosarcoma, recurrent adult brain neoplasm